Cargando…
One Giant Leap from Mouse to Man: The Microbiota–Gut–Brain Axis in Mood Disorders and Translational Challenges Moving towards Human Clinical Trials
The microbiota–gut–brain axis is a bidirectional communication pathway that enables the gut microbiota to communicate with the brain through direct and indirect signaling pathways to influence brain physiology, function, and even behavior. Research has shown that probiotics can improve several aspec...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8840472/ https://www.ncbi.nlm.nih.gov/pubmed/35276927 http://dx.doi.org/10.3390/nu14030568 |
_version_ | 1784650627964469248 |
---|---|
author | Forssten, Sofia D. Ouwehand, Arthur C. Griffin, Síle M. Patterson, Elaine |
author_facet | Forssten, Sofia D. Ouwehand, Arthur C. Griffin, Síle M. Patterson, Elaine |
author_sort | Forssten, Sofia D. |
collection | PubMed |
description | The microbiota–gut–brain axis is a bidirectional communication pathway that enables the gut microbiota to communicate with the brain through direct and indirect signaling pathways to influence brain physiology, function, and even behavior. Research has shown that probiotics can improve several aspects of health by changing the environment within the gut, and several lines of evidence now indicate a beneficial effect of probiotics on mental and brain health. Such evidence has prompted the arrival of a new term to the world of biotics research: psychobiotics, defined as any exogenous influence whose effect on mental health is bacterially mediated. Several taxonomic changes in the gut microbiota have been reported in neurodevelopmental disorders, mood disorders such as anxiety and depression, and neurodegenerative disorders such as Alzheimer’s disease. While clinical evidence supporting the role of the gut microbiota in mental and brain health, and indeed demonstrating the beneficial effects of probiotics is rapidly accumulating, most of the evidence to date has emerged from preclinical studies employing different animal models. The purpose of this review is to focus on the role of probiotics and the microbiota–gut–brain axis in relation to mood disorders and to review the current translational challenges from preclinical to clinical research. |
format | Online Article Text |
id | pubmed-8840472 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88404722022-02-13 One Giant Leap from Mouse to Man: The Microbiota–Gut–Brain Axis in Mood Disorders and Translational Challenges Moving towards Human Clinical Trials Forssten, Sofia D. Ouwehand, Arthur C. Griffin, Síle M. Patterson, Elaine Nutrients Review The microbiota–gut–brain axis is a bidirectional communication pathway that enables the gut microbiota to communicate with the brain through direct and indirect signaling pathways to influence brain physiology, function, and even behavior. Research has shown that probiotics can improve several aspects of health by changing the environment within the gut, and several lines of evidence now indicate a beneficial effect of probiotics on mental and brain health. Such evidence has prompted the arrival of a new term to the world of biotics research: psychobiotics, defined as any exogenous influence whose effect on mental health is bacterially mediated. Several taxonomic changes in the gut microbiota have been reported in neurodevelopmental disorders, mood disorders such as anxiety and depression, and neurodegenerative disorders such as Alzheimer’s disease. While clinical evidence supporting the role of the gut microbiota in mental and brain health, and indeed demonstrating the beneficial effects of probiotics is rapidly accumulating, most of the evidence to date has emerged from preclinical studies employing different animal models. The purpose of this review is to focus on the role of probiotics and the microbiota–gut–brain axis in relation to mood disorders and to review the current translational challenges from preclinical to clinical research. MDPI 2022-01-27 /pmc/articles/PMC8840472/ /pubmed/35276927 http://dx.doi.org/10.3390/nu14030568 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Forssten, Sofia D. Ouwehand, Arthur C. Griffin, Síle M. Patterson, Elaine One Giant Leap from Mouse to Man: The Microbiota–Gut–Brain Axis in Mood Disorders and Translational Challenges Moving towards Human Clinical Trials |
title | One Giant Leap from Mouse to Man: The Microbiota–Gut–Brain Axis in Mood Disorders and Translational Challenges Moving towards Human Clinical Trials |
title_full | One Giant Leap from Mouse to Man: The Microbiota–Gut–Brain Axis in Mood Disorders and Translational Challenges Moving towards Human Clinical Trials |
title_fullStr | One Giant Leap from Mouse to Man: The Microbiota–Gut–Brain Axis in Mood Disorders and Translational Challenges Moving towards Human Clinical Trials |
title_full_unstemmed | One Giant Leap from Mouse to Man: The Microbiota–Gut–Brain Axis in Mood Disorders and Translational Challenges Moving towards Human Clinical Trials |
title_short | One Giant Leap from Mouse to Man: The Microbiota–Gut–Brain Axis in Mood Disorders and Translational Challenges Moving towards Human Clinical Trials |
title_sort | one giant leap from mouse to man: the microbiota–gut–brain axis in mood disorders and translational challenges moving towards human clinical trials |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8840472/ https://www.ncbi.nlm.nih.gov/pubmed/35276927 http://dx.doi.org/10.3390/nu14030568 |
work_keys_str_mv | AT forsstensofiad onegiantleapfrommousetomanthemicrobiotagutbrainaxisinmooddisordersandtranslationalchallengesmovingtowardshumanclinicaltrials AT ouwehandarthurc onegiantleapfrommousetomanthemicrobiotagutbrainaxisinmooddisordersandtranslationalchallengesmovingtowardshumanclinicaltrials AT griffinsilem onegiantleapfrommousetomanthemicrobiotagutbrainaxisinmooddisordersandtranslationalchallengesmovingtowardshumanclinicaltrials AT pattersonelaine onegiantleapfrommousetomanthemicrobiotagutbrainaxisinmooddisordersandtranslationalchallengesmovingtowardshumanclinicaltrials |